“I have been using K9 Liquid DX since July 2024. Compared to tissue sequencing (that we were doing before Cancan existence), liquid biopsy helps us on a regular basis. Owners need explanation but are usually well aware of its existence in human medicine.

We use it to identify residual disease. An interesting purpose is when owners hesitate to start chemotherapy. For instance, after local treatment for cancer where we do not have the ability to prove the benefits of chemotherapy through literature. For instance, an histologic intermediate grade mammary cancer after surgery with negative CT staging.

We use it to monitor our treatment efficacy. For instance, with soft tissue sarcoma post surgery and radiation therapy. Did we obtain a microscopic cure? We know from previous studies that liquid biopsy is a better assessment of the recurrence risk than the histological grade is.

We use it as well to offer treatment option based on genomic alteration providing we can identify targetable genomic alteration documented in the literature with enough pharmacokinetics data. These treatments are always offered as an option after gold standard. And they represent a therapeutic option when none is available like a post surgical adjuvant treatment for soft tissue sarcoma.

Finally, we also use liquid biopsy to search for P53 mutation before implementing a cancer autovaccination (no vaccine with P53 mutation present)

I also like to use both K9 tissue Dx and K9 liquid Dx when possible, in order to obtain a ’tissue informed liquid biopsy’ and to maximize the signification of my results. 

All together, Cancan is, in my opinion, a great tool, easy to use, affordable cost for the owners. It is also a unique opportunity for the Veterinary oncologists to build real world data knowledge. And one of the rare solutions to offer our pets and clients new therapeutic options, desperately needed in canine and feline oncology. There is still a long way to go to build strong clinical data but in my nearly 35 years of experience practicing oncology, after CT, radiation therapy and soft tissue surgery skills, use of liquid biopsy is probably the next paradigmatic change in our practice.”